Roche has reported promising results for its experimental multiple sclerosis (MS) drug, fenebrutinib, after late-stage clinical trials showed a 55% reduction in annualized relapse rates compared with an active treatment. The findings could offer new hope for people living with MS who need effective options to manage relapses and slow disease progression.
Announced on October 21, 2026, the results add to growing interest in new MS drugs coming out in 2026. Fenebrutinib is an oral medication being developed to address disease activity both inside and outside the brain. However, the treatment remains investigational and must undergo the relevant regulatory review before it can become widely available.
What Is Roche’s New MS Drug Fenebrutinib?
Fenebrutinib is an experimental oral medicine developed by Roche that belongs to a class of drugs known as Bruton’s tyrosine kinase (BTK) inhibitors. These medicines target a protein involved in the activity of certain immune cells that contribute to inflammation.
Multiple sclerosis is a chronic condition in which the immune system damages the protective covering of nerves. This damage can cause symptoms such as fatigue, vision problems, muscle weakness, and difficulties with movement.
The goal of fenebrutinib is to control inflammatory activity while also addressing processes linked to long-term damage inside the central nervous system.
Fenebrutinib Phase 3 Trials Show Reduced Relapses
The latest fenebrutinib Phase 3 findings come from Roche’s FENhance 1 and FENhance 2 trials, which studied people with relapsing multiple sclerosis.
The combined results showed that fenebrutinib reduced annualized relapse rates by 55% compared with teriflunomide, an established MS treatment, over 96 weeks.
Roche also reported improvements in measures related to brain volume loss and disability progression. These findings may help researchers understand whether the treatment can provide benefits beyond reducing the frequency of relapses.
The results are encouraging, but further regulatory assessment and additional evidence will be important in determining the treatment’s future role.
How Does a BTK Inhibitor Work in Multiple Sclerosis?
A BTK inhibitor works by targeting a protein involved in immune-cell signaling. In MS, this approach may help regulate B cells and microglia, immune-related cells associated with inflammation in the body and brain.
The Roche BTK inhibitor for multiple sclerosis is designed to cross the blood-brain barrier, allowing it to reach the central nervous system. This feature may be important for addressing chronic inflammation associated with disease progression.
If approved, fenebrutinib could provide an additional oral treatment option for eligible patients. Its safety, effectiveness, and suitability for different forms of MS will remain important considerations.
Fenebrutinib vs Ocrevus: What Is the Difference?
People searching for fenebrutinib vs Ocrevus are comparing two treatments developed for multiple sclerosis.
Fenebrutinib is an investigational oral BTK inhibitor, while Ocrevus (ocrelizumab) is an approved treatment administered by infusion or injection, depending on the formulation and location.
The medicines work through different biological mechanisms. In its Phase 3 FENtrepid study for primary progressive MS, fenebrutinib met its primary endpoint of non-inferiority compared with Ocrevus in reducing disability progression. This does not establish that fenebrutinib is superior to Ocrevus.
What Does This Mean for New MS Drugs Coming Out in 2026?
The latest results place fenebrutinib among the treatments attracting attention in the search for new MS drugs coming out in 2026. Researchers are increasingly exploring medicines that can control relapses while also addressing long-term neurological damage.
For patients, the development of new therapies may eventually expand treatment choices. However, availability will depend on regulatory decisions, safety reviews, and the final clinical evidence.
Roche’s Fenebrutinib Advances MS Treatment Research
Roche’s latest findings highlight continued progress in multiple sclerosis research. The reported 55% reduction in relapse rates suggests that fenebrutinib could become an important treatment candidate if regulators approve it.
For now, patients and healthcare professionals will need to await further regulatory developments. The next stage will determine whether this experimental medicine can translate promising clinical results into an additional treatment option for people living with multiple sclerosis.
Visit: The Entrepreneur Insights Website.
Leave a comment